- Home
- BOF vs NXL Comparison
BOF vs NXL Comparison
Compare BOF & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOF
- NXL
- Stock Information
- Founded
- BOF 2017
- NXL 2010
- Country
- BOF United States
- NXL United States
- Employees
- BOF N/A
- NXL N/A
- Industry
- BOF Packaged Foods
- NXL Medical Specialities
- Sector
- BOF Consumer Staples
- NXL Health Care
- Exchange
- BOF Nasdaq
- NXL Nasdaq
- Market Cap
- BOF 21.2M
- NXL 21.0M
- IPO Year
- BOF 2023
- NXL 2022
- Fundamental
- Price
- BOF $2.69
- NXL $1.00
- Analyst Decision
- BOF
- NXL Strong Buy
- Analyst Count
- BOF 0
- NXL 1
- Target Price
- BOF N/A
- NXL $5.00
- AVG Volume (30 Days)
- BOF 103.4K
- NXL 79.3K
- Earning Date
- BOF 08-13-2025
- NXL 08-07-2025
- Dividend Yield
- BOF N/A
- NXL N/A
- EPS Growth
- BOF N/A
- NXL N/A
- EPS
- BOF N/A
- NXL N/A
- Revenue
- BOF $8,242,843.00
- NXL $131,065.00
- Revenue This Year
- BOF N/A
- NXL $79.59
- Revenue Next Year
- BOF N/A
- NXL $334.65
- P/E Ratio
- BOF N/A
- NXL N/A
- Revenue Growth
- BOF 96.47
- NXL N/A
- 52 Week Low
- BOF $0.61
- NXL $0.59
- 52 Week High
- BOF $4.11
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- BOF 62.25
- NXL 37.97
- Support Level
- BOF $2.46
- NXL $0.96
- Resistance Level
- BOF $2.87
- NXL $1.03
- Average True Range (ATR)
- BOF 0.18
- NXL 0.07
- MACD
- BOF 0.04
- NXL 0.01
- Stochastic Oscillator
- BOF 79.78
- NXL 45.70
About BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.